Foghorn Therapeutics Q3 net loss narrows to $14.3M; cash runway into H1 2026

Foghorn Therapeutics Inc.

2023-Q3 EPS reported -$1.77 revenue$28,386,000

Net loss $14.3M vs $25.8M YoY; collaboration revenue $17.5M incl. Merck termination.
Cash, equivalents, marketable securities $259.9M as of Sept 30; runway into H1 2026.
First patient dosed in FHD-286 combo study in AML; data expected H2 2024.
Transitioned BRM Selective inhibitor program to Loxo@Lilly under collaboration.
Preclinical data for EP300 and CBP selective degraders show tumor growth inhibition and no thrombocytopenia.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Foghorn Therapeutics Inc. reported quarter ended September 30, 2023 results: revenue $17.5 million, net income $14.3 million.

Period: quarter ended September 30, 2023
Revenue: $17.5 million
Net income: $14.3 million
Result: reported results

Exact text from the filing

$259.9 million in c ash, cash equivalents and marketable securities, which provides cash runway into the first half of 2026 . • Collaboration Revenues. Collaboration revenue was $17.5 million for the three months ended September 30, 2023, compared to $6.6 million for the three months ended September 30, 2022. The increase year-over-year was primarily driven by revenue

View on SEC.gov

Browse all earnings releases →

Foghorn Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-036179

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.